Last reviewed · How we verify
NCT03472313
Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects
Phase 1 trial testing [18F]MNI-958 in Healthy Volunteers in 2 participants. Completed in 20 April 2018.
20 April 2018
Quick facts
| Lead sponsor | Invicro |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 2 |
| Start date | 14 November 2017 |
| Primary completion | 20 April 2018 |
| Estimated completion | 20 April 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- [18F]MNI-958 — full drug profile →
Conditions studied
- Healthy Volunteers — all drugs for Healthy Volunteers →
Sponsor
Invicro — full company profile →
Who can join
Adults 18 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-958 also known as APN-0000455 or PM-PBB3, as a tau targeted radiopharmaceutical.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03472313
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of [18F]MNI-958
Trials testing the same drug.
- NCT03545789 — Phase 1 Test-retest Evaluation of [18F]MNI-958 PET · Phase 1 · completed
- NCT03058965 — Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain · EARLY_PHASE1 · completed
Other recruiting trials for Healthy Volunteers
Currently open trials in the same condition.
- NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
- NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
- NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
- NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
- NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
Other Invicro trials
Trials by the same sponsor.
- NCT05274568 — Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein · Phase 1 · completed
- NCT05164536 — Plasma P-tau2017 and Quantitative Amyloid PET Imaging · Phase 1 · completed
- NCT05009199 — Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444 · Phase 1 · completed
- NCT05005819 — Evaluation of [18F]APN-1607 as a PET Biomarker · Phase 1 · completed
- NCT06445465 — Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain · EARLY_PHASE1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03472313 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Invicro
- Last refreshed: 22 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03472313.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing